Replimune Group shares fall 1.73% premarket after FDA meeting fails to determine accelerated approval pathway for RP1.

Replimune Group, Inc. fell 1.73% in premarket trading, following a 45% drop in intraday trading on September 18, 2025. The company announced that it completed a Type A meeting with the FDA on September 16 to discuss its Biologics License Application (BLA) for RP1, but a path forward under the accelerated approval pathway has not been determined. This uncertainty led to a sharp decline in the stock price, with shares falling 39% to $3.49 in early trading on September 18, 2025.